



Issued by the Standards Unit, UK Health Security Agency Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 1 of 37

Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on the UK SMI website. UK SMIs are developed,



Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 2 of 37

UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

Contents

Con	tents	3
Ame	ndment table	
1	General information	
2	Scientific information	5
3	Scope of document	
4	endment table General information Scientific information Scope of document Introduction	7
5		9
6	Technical information and/or limitations	12
7	Technical information and/or limitations	12
8		13
9	Laboratory processes (analytical start)	15
10	Pre-laboratory processes (pre-analytical stage) Laboratory processes (analytical stage) Post-laboratory processes (post praiytical stage) Mandatory Reporting of <i>C</i> officile infection Antimicrobial Susceptibility Testing Referral to reference of specialist testing laboratories endix: <i>C. difficile</i> of ture and Identification	17
11	Mandatory Reporting of <i>Conficile</i> infection	22
12	Antimicrobial Susceptionility Testing	23
13	Referral to reference or specialist testing laboratories	24
Арр	endix: <i>C. difficile</i> uture and Identification	25
Pofe	erences	

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Amendment number/date	x/dd.mm.yy
Issue number discarded	Jar Land
Insert issue number	.1 50
Anticipated next review date*	dd.mm.yy
Section(s) involved	dd.mm.yy Amendment
	<u>1</u> 01
Reviews can be extended up to 5	years where appropriate
Anticipated next review date* Section(s) involved	years where appropriate

General information 1

View general information related to UK SMIs.

 Scope of document
 This UK SMI describes the investigation of faeces for *Clostridioides difficite* of laboratory interpretation of results, and the reporting of *C. difficile* infection (CDI) is based saboratory testing (1-5). No single test is aboratory diagnosis of C. and the results of the saboratory diagnosis of C. and the saboratory stage testing approach is required followed by a third test where the primary test is positive and the secondary test is negative (2-5,8,9). A sensitive C. difficile glutamate dehydrogenase (GDH) immunoassay or Nucleic Acid Amplification Test (NAAT) is recommended as a primary test followed by a highly specific toxin A and B immunoassay (2-5,8,9).

For the management and treatment of C. cile infections, clinicians should assess the patient's current clinical condition and refer to the relevant guidance e.g., the National Institute for Health and Care Excellence (NICE), the Healthcare Infection Society (HIS) and the Scottish Antimicrobial Prescribing Guidance (SAPG) guidelines (10-12).

Please refer to UK SMI S Sastroenteritis and UK SMI ID 8 - Identification of Clostridium species for additional information.

This UK SMI should with other UK SMIs.

Definitions N

	Key terms	Definition
nei	Diarrhoe	Stools of a loose or liquid consistency (typically classed as 5 to 7 on the Bristol Stool Form Scale) occurring more frequently than is normal for the individual. Usually at least \geq 3 instances in a 24- hour period; however, the consistency of stools is a more important indicator than the frequency (13-15).
ansi		Diarrhoea may be associated with symptoms such as abdominal cramps, nausea, malaise, vomiting, fever and dehydration.
<u>_</u> 0`		Note: In high-risk individuals and settings where transmission of infection is a concern, strict reliance on 3 or more episodes of diarrhoea within 24 hours to instigate testing and pre-emptive patient isolation may be inappropriate. Therefore, some flexibility is required to ensure that unexplained diarrhoea is appropriately investigated and managed (2).

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 5 of 37

Introduction 4

Clostridioides difficile infection (CDI) remains a significant health concern in the UK, with a substantial increase in CDI cases (16-19). In the 2022 - 2023 financial year, annual CDI cases in England increased by 11.3% with a rate of 27.6 infections per 100,000 population compared to the previous financial year (2021 - 2022) (16). An increase in both community and hospital-onset CDI was observed, with communityonset being disproportionally higher at 58.3% (16). The reason for the recent rise in Therefore, continued surveillance with enhanced testing is crucial to support infection and control interventions for the management of the increasing incide of CDI.

2025

C. difficile is a Gram positive, spore forming, strictly anaerobic rod, so name because of the difficulty in original culture and characterisation (20,21). The taxonomic differences between this species and other members of the *Clostricium* genus is reflected by the change in nomenclature to *Clostridioides* (22-24) Coxigenic *C. difficile* strains produce two large, structurally similar protein toxins (A **CR** B), which are the main virulence factors in CDI (25). C. difficile can colonise the old of and may cause a spectrum of disease in humans, from a self-limiting mild distribution to the advanced and severe illness characterised by pseudomembraneus colitis (PMC).

Transmission of C. difficile is via the faeco-oral route CDI is predominantly healthcare-associated but can be isolated from soil, water, hospital and domiciliary environments as well as animal faeces, all of which can act as a reservoir for crossinfection (26). These may be a source of infection where infection prevention and control are inadequate.

4.1 Pathogenicity The production of the enterotoxic oxin A (TcdA), and cytotoxin, toxin B (TcdB) by *C. difficile* causes cell death (2). These toxins (type III exotoxins which glycosylate and inactivate intracellular Fbo-family GTPases resulting in changes in the actin cytoskeleton) cause the characteristic mucosal damage consisting of plaque-like lesions which may, in the cases, result in the formation of pseudomembranes in the colon (21).

In strains which cossess the toxin gene, toxin production is controlled by toxin regulatory review and can occur in response to various conditions such as the presence of antibiotics or specific nutrients. Only strains that possess the pathogenic locus (RaLoc) carry the genes for the toxins A (TcdA) and B (TcdA) and can cause CDKXY). Strains that lack PaLoc do not produce these toxins and are generally nonospogenic (i.e., non-toxigenic strains), and therefore do not cause CDI. Most pathogenic strains produce both TcdA and TcdB, however, clinically significant strains causing diarrhoea and colitis have been isolated which are TcdA negative and TcdB positive (27). Outbreaks caused by these strains have been documented and although TcdA positive and TcdB negative strains have not been recorded, it is essential to use diagnostic toxin immunoassays capable of detecting both toxins (28). Some NAATs only target either toxin A (tcdA) or toxin B (tcdB) genes. This is suitable if those that only detect toxin A genes target the conserved portion of the tcdA gene and not the truncated region, which is absent in C. difficile strains that do not produce TcdA enterotoxin.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 7 of 37

Deletions in the toxin regulatory gene *tcdC* are associated with greater production of TcdA and TcdB as described in the hypervirulent C. difficile strain 027 (29,30). In addition, around one third of strains of C. difficile produce a binary toxin (CDT) which is not part of PaLoc and therefore may be present in the absence of TcdA and TcdB. This toxin may contribute to the severity of infection in certain hypervirulent strains,

Acquisition of *C. difficile* alone does not induce CDI. Individuals may be *C. difficile* carriers (i.e., have asymptomatic colonisation) of either non-toxigenic or toxigenic strains of *C. difficile*. For asymptomatic carriage of toxigenic strains to progression CDI, other contributing factors are often required.

prevention and control measures, especially when the patient has bose stools, given the carrier state and the potential for contamination of the environment with C. difficile.

The incidence of C. difficile colonisation varies in the literature, influenced by factors such as study population and epidemiological differences. Some studies report that around 2% of the general population is colonised with toxigenic *C. difficile* strains. In hospitalised patients, this rate can be as high as 7 - 25% of hospitalised patients (32-35). *C. difficile* has also been found in up to 50% of infants, who may become colonised in the first few months on the disease is rarely present at this are (20.27). this age (36,37).

The main risk factor for CDI is the repeated use of broad-spectrum antibiotics that alter or distort the normal microbiote changes in the human gut microbiota, associated with antibiotic therapy or other treatments such as chemotherapeutic and radiotherapeutic agents permits asymptomatic colonisation by *C. difficile* (38). The over-growth of toxin-producing strains of C. difficile can damage the lining of the colon leading to the development of CDI.

Almost all drugs with antibacterial spectrum of activity have been implicated causally in CDI. The host frequently implicated drugs are those which have a marked detrimental effect on the microbiota of the colon. These include broad spectrum beta lactams, ceptopsporins, clindamycin and fluoroquinolones (39).

Other risk factors for the development of CDI include immunosuppression, advanced age, parents undergoing general surgery and underlying co-morbidities such as chronic renal disease, inflammatory bowel disease and cancer (40-43). The rtance of age can be demonstrated by figures from the UKHSA annual summary port on C. difficile infections which show that the highest proportion of cases (in Which age was reported) were from patients > 65 years old (16).

The spectrum of *C. difficile* disease ranges from asymptomatic carriage, through a self-limiting mild diarrhoea to the advanced and severe illness characterised by pseudomembranous colitis (44). Severe colitis, with or without pseudomembranes, can result in partial or complete ileus or toxic megacolon, perforation, and death (21). If present, pseudomembranous colitis is seen on endoscopy. Endoscopy is not routinely indicated but is diagnostic in, for example, suspected cases of 'silent' CDI,

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 8 of 37

such as ileus, toxic megacolon or pseudomembranous colitis without diarrhoea such that submission of a stool specimen for laboratory testing is impossible (44). It may also be useful when CDI is suspected but laboratory testing for CDI consistently yields negative results. In such circumstances, rectal swabs, peripheral white cell count (WCC), serum creatinine and abdominal imaging such as CT (computerised

Treatment and management guidelines for CDI are produced in the United Kingdom by the National Institute for Health and Care Excellence (NICE), the Healthcare Infection Society (HIS), and the Scottish Antimicrobial Prescribing Control (10-12). Outside of the United Kingdom them European Society of Clinical Microbiology and Infectious Diseases (ESCM) and Infectious Disease Society of America (IDSA) (46-48).

Scotland follow their respective National Infection, Prevention and Control Manuals, which England and Wales have also adopted (49,50). While North Ireland adhere to their own National Infection, Prevention and Control Manuals (51).

In the UK, the overall 30-day case fatality rate of CDI remains relatively high at around 13% with a CDI mortality rate of 3.8 deaths per 100,000 population (2022-2023 FY) (52). Recurrence of CDI occurs in around 15-25% optimary cases, which rises to 65% of cases having a recurrence after a third estimates subsequent episode (47,53-55).

C. difficile infection diagnostic tests 5

This section describes the tests and the for CDI diagnosis. Refer to Section 9 and 10 for the order of CDI testing.

5.1 Glutamate dehydrogenase antigen detection assays

GDHs are a group genzymes abundantly present in all bacteria, including toxigenic and non-toxigenic trains of C. difficile. The GDH of C. difficile can therefore be used as an accurate marker for the presence of C. difficile in faecal samples. To avoid cross-reactively with other prokaryotic and eukaryotic GDH enzymes, relatively specific monoclonal antibodies are raised to C. difficile-specific GDH. GDH assays are commercially available as membrane assays and enzyme immunoassays (EIAs) and are suck to perform and comparatively inexpensive.

We GDH antigen test has a high clinical sensitivity but is less specific than C. difficile oxin-based assays as it detects both toxigenic and non-toxigenic strains. It is therefore useful as a primary test when used in conjunction with more specific confirmatory test(s). Same day reporting of negative samples is achievable with this method as GDH negative results do not need further testing for C. difficile. The role of GDH in the detection of C. difficile has been the focus of several studies which have recognised its effective use in a dual test approach to testing (9,56-58).

5.2 Molecular methods

NAATs, and particularly PCR assays, have been used to target C. difficile toxin A and B genes in faeces (59). Assays which detect C. difficile toxin gene(s) demonstrate the potential to produce toxins by a C. difficile strain in a patient's sample (60). The

In addition, there are several multiplex molecular gastrointestinal pathogen panels both rapid and analytically sensitive with results for gastrointestinal pathogen panels returning in less than a day (61,62). Some of these molecular gastrointestinal pathogen based only the toxin B gene, but also other is strain ribotype 027 contents. these tests for CDI, in comparison with toxin A and B immunoasses, these tests should not be used alone as a diagnostic test for *C. difficile* (72,65). NAAT testing, as with GDH detection, may detect asymptomatic carriag of *C. difficile* (7,65,66).

5.3 Toxin A & B antigen detection assays

There are numerous commercially available toxin A and B immunoassay tests intended to detect *C. difficile* toxins. Use of improvoassays that detect both toxins A and B is essential, as infection due to A negative but B positive strains have been recorded (27,67). *C. difficile* toxin assays are commercially available as membrane assays and well-based EIAs and are quick to perform and relatively inexpensive. As with all assays, the analytical and clinical sensitivity/specificity of these kits vary, although, in general *C. difficile* toxin timmunoassays lack clinical sensitivity, if used alone, but are highly specific for CDI. For this reason, they should be used in a two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (68-73).

5.4 Other methods5.4.1 Cell-Optiotoxicity neutralisation assay (Cell-culture)

Although resarded as the "gold standard", use of tissue culture for the detection of C. difficile wins by virtue of its cytopathic effect (CPE) (neutralisable with C. sordellii antite (i), has now been surpassed by other methods. The required technical tise, the unavailability of the antitoxin in the UK, and usually a 24 to 48-hour be ay for the final result in comparison to other methods has made this method no onger viable (74).

Tissue culture, especially with vero cells, could also detect other faecal cytotoxins that are associated with diarrhoea e.g., C. perfringens enterotoxin although this is mitigated by the use of the neutralising antitoxin (75). CPE that is not neutralised by C. sordellii antitoxin may indicate that another pathogen is present. The unavailability of antitoxin in the UK, however, means this method is also not feasible for use.

5.4.2 Faecal calprotectin

Some studies have investigated faecal calprotectin (an indicator of general intestinal inflammation) as an adjunctive method to diagnose CDI. Although the sensitivity of this test is high, it lacks specificity and is therefore not recommended (76).

Cutture has limited clinical utility for the diagnosis of CDI due to its loration
 Cutture has limited clinical utility for the diagnosis of CDI due to its loration
 Cutture has limited clinical utility for the diagnosis of CDI due to its loration

In Scotland laboratory culture of faeces is recommended in cases of severe disease, suspected outbreaks, in recurrent cases (> 28 days and < 56 days) and as part of the <u>C. difficile snapshot programme</u>. In England and Northam Ireland culture may be undertaken by the CDRN. In Wales, all GDH/NAAT positive samples should be referred to the LIKA PLI for C. difficile subtract referred to the UKARU for C. difficile culture.

5.6 Typing of Clostridioides of

Typing of isolates of *C. difficile* is used in the investigation of increased frequency of CDI, to determine potential transmission, as well as in cases of increased severity, complication, recurrence or death ate presumptively associated with CDI (77). Historically, many typing techniques have been used in the investigation of outbreaks of CDI. Those in recent use are exclusively DNA-based (78-80).

PCR-ribotyping in completion with multilocus variable-number tandem-repeat analysis (MLVA) and more recently, analysis of whole genome sequencing (WGS) data, are techniques used witinely to distinguish isolates of C. difficile in the UK (78).

The culture of identification of *C. difficile* is important for typing in cases of increased incidence, in outbreak situations and for general surveillance, including drug resistance and virulence determinant detection.

Purce or isolate of C. difficile is required for typing. Please refer to the popriate UK *C. difficile* typing services in Section 13 for specific requirements.

5.6.1 PCR Ribotyping and MLVA

PCR ribotyping is an internationally recognised method for typing of C. difficile isolates, based on 16S-23S intergenic spacer region diversity. More than 1,100 PCR ribotypes have now been identified (81-83).

The MLVA technique offers enhanced fingerprinting of C. difficile isolates and can be used to determine closely related isolates (and help identify transmission) in settings where PCR-ribotyping data are insufficient (78,79).

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 11 of 37

5.6.2 Whole Genome sequencing

Whole genome sequencing allows the comparison of entire microbial genomes and has emerged as an important tool in the epidemiological study of *C. difficile*. This technique can simultaneously detect sequences that (i) encode toxin genes and other virulence factors (ii) potentially confer resistance to antibiotics, and (iii) facilitate the measurement of relatedness between *C. difficile* strains with high resolution. WGS-based typing can be undertaken using traditional, core- or whole-genome MLST (cgMLST/wgMLST). Alternatively, single-nucleotide polymorphism (SNP) typing offers ultimate discriminatory power (78). Therefore, analysis of whole genome sequence data may allow surveillance of emerging lineages with higher transmissibility and important genetic markers.

6 Technical information and/or limitations

6.1 General considerations

As with all laboratory tests, *C. difficile* assays may vary in the analytic and clinical sensitivity and specificity, with some performing particularly poorly. Therefore, it is crucial for laboratories to understand the strengths and limitations of any method they employ for detection of *C. difficile*, and its toxins.

Manufacturer's instructions should be followed and all test kits and NAAT platforms should be validated and verified prior to use

Laboratories should also incorporate these assays within the recommended two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (see section 8). This is because the detection of *C. difficile* by culture, GDH test or by NAAC alone has a poor specificity for the diagnosis of *C. difficile* infection. These methods do not detect toxin produced by *C. difficile* but instead detect the presence of the bacterium or the genes for toxin production (7).

Therefore, detection **of S**. *difficile* in an individual's faeces by one of these tests when it is used as the only method of detection does not necessarily mean that the patient has toxin-mediates C. *difficile* infection, and careful clinical correlation is required. Alternative aetologies should be sought in such cases.

7 . Safety considerations

This election covers specific safety considerations related to this UK SMI and should be read in conjunction with the general <u>safety considerations</u> (81-101)

7.1 Specimen Collection, Transport and Storage

Collect specimens using aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 12 of 37

UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

7.2 Specimen Processing

Processing of specimens should be carried out in a containment level 2 laboratory, as a minimum.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

The above guidance should be supplemented with local COSHH and risk assessments.

8

8.1 Eligibility criteria for testing:

Pre-laboratory processes (pre-analytical store) Eligibility criteria for testing: In all UK nations, faecal specimens that meet the testing criteria muld be tested for CDI. This includes all specimens of diarrhoea* that are not attroctable to an underlying condition e.g., inflammatory colitis or therapy e.g., atives. Also, in all UK nations screening of symptom-free patients and clearance string is not recommended.

*Please refer to the Scope of the document and Section 8.3.1 for the definition of diarrhoea and correct specimen type, respective

In the UK (except Scotland) faecal specimens that meet the testing criteria should be tested for C. difficile from:

 Ideally, all patients aged ears old.

Acknowledging that resources may not allow testing of all patients ≥ 2 years old, as a minimum, the following patients should be tested:

- All hospital patients aged ≥ 2 years old.
- All community patients \geq 65 years old.

-jonsultati

Community patients < 65 years old where clinically indicated, which includes **Not** limited to:

If C. difficile mentioned in request clinical details

- If the patient is recognised by the testing laboratory, microbiologists or IPC team as previously having C. difficile;
- If current or prior antibiotic therapy is mentioned; 0
- If a hospital admission is mentioned; 0
- If residence at a care home or other community care facility is indicated \cap by the patient address, or mentioned on the request form;
- o Immunocompromised (e.g. transplant patients, patients on chemotherapy)

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 13 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

- Inflammatory bowel disease (IBD; e.g. Crohn's disease or Ulcerative Colitis)
- Abdominal surgery
- Chronic renal/kidney disease (CKD);

vvhen specifically requested
 Note: CDI is not confined to the groups above and may not have been considered by the requestor. Half of community CDI cases may be undetected because of absence of clinical suspicion, accounting for three times more undiaged in the community compared with hospitals in one statement.

In Scotland, faecal specimens that meet the testing criteria should be tested for C. difficile in patients from:

All patients ≥ 3 years old.

Notes:

Under the mandatory surveillance programme, microsoft CDI cases aged 15 and above need to be reported to ARHAI scotland (5). However, it is recommended that patients aged 3 - 14 with omirmed CDI are also reported for surveillance purposes.

In Scotland, a case of CDI used for manuatory reporting is defined as someone in whose stool C. difficile toxin has the identified at the same time as they have experienced diarrhoea not exhibitable to any other cause, or from whose stool C. difficile has been cultured at the same time as they have been diagnosed with pseudoments anous colitis (PMC) (5).

8.2 Specimen t

Faeces

Note: Rectal swab may be used as an alternative to stool samples in cases where stool collection is not feasible. They can also aid in diagnosing silent CDI (paralytic ileus, toxic merecolon, or pseudomembranous colitis) without diarrhoea alongside other diagnostic methods such as colonoscopy or clinical indicators (1,4,45,103-105). However, rectal swabs should be analysed using molecular methods (4,45,103-105).

becimen Collection

safety considerations refer to Section 7.

Faecal samples from symptomatic patients should be taken at the earliest point C. difficile is expected.

A liquid specimen of 1 - 2mL is sufficient for culture and toxin detection.

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 14 of 37

Note: It is not recommended to wait for three episodes of diarrhoea to occur prior to initiate testing in settings where transmission of infection is a concern (2).

8.3.1 Correct specimen type and method of collection

Specimens may be passed into a clean, dry, disposable bedpan or similar container and transferred into a CE marked leak proof container. The specimen is unsatisfactory if any residual soap, detergent, or disinfectant remains in the pan. Samples mixed with large amounts of urine are also unsuitable.

Ideally, the sample container should be one quarter full (to indicate the patient has diarrhoea) and the sample should take the shape of the container. Formed stools are usually unsuitable for investigation for *C. difficile*. These should be rejected with the appropriate comment appended to the report, unless specifically requested by a consultant microbiologist or equivalent.

8.4 Transport and Storage

Specimens should be transported and processed as soon as persole.

If processing is delayed, refrigeration at 4°C is preferable to sorage at ambient temperature. Refrigerate for up to the time indicated in the manufacturer's recommendations if unable to process within two hours. Freezing samples at -20°C compromises faecal toxin testing (106). Therefore the sesential to conduct toxin tests before long-term freezing and thawing of samples for subsequent culturing and typing (3,5,106)

All *C. difficile* toxin immunoassay positive faceal samples should be kept refrigerated or frozen, for culture and subsequent typing, which may be required in certain situations e.g., an outbreak or as part of surveillance (107).

Where capacity allows, storage of the immunoassay negative but NAAT positive samples may be useful, as transmission may only be apparent when these strains are typed. It is not necessary to keep the whole specimen, a small aliquot Eppendorf will suffice (108). The duration of storage needs to be determined locally but should allow for appropriate outbreal investigation, where necessary (99).

9 Laboratory processes (analytical stage)

9.1 C Mificile infection diagnostic procedure

A two stage testing approach with a third test where the primary test is positive and secondary test is negative is required (2-5).

This consists of a GDH immunoassay or NAAT followed by a toxin A and B immunoassay (2,4,8). Where GDH and toxin immunoassay testing are initially conducted and a discordant result obtained, i.e., one result is positive and the other negative, a NAAT should be performed as a reflex test to distinguish between toxigenic and non-toxigenic samples (2,4,8). The requirements for further *C. difficile* culture and identification vary by nation, refer to Section 5.5.1 *C. difficile* culture.

In Scotland laboratory culture of faeces is recommended in cases of severe disease, suspected outbreaks and as part of <u>*C. difficile* snapshot programme</u> (5).

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 15 of 37

In England and Northern Ireland culture may be undertaken by the CDRN.

Consultation between 23 December 2024 and 11 January 2025 In Wales, all GDH/NAAT positive samples should be referred to the UKARU for

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 16 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

10 Post-laboratory processes (post analytical stage)

10.1 Interpreting and reporting laboratory results

No single test is reliable as a stand-alone test for diagnosing *C. difficile* infection. A GDH, single-plex NAAT or gastrointestinal panel multiplex NAAT positive test is not sufficient for the diagnosis of CDI (see sections 5 and 6). A two-stage testing approach followed by a third test where the primary test is positive and the secondary test is negative (see footnote*) is advised for the diagnosis of CDI as outlined in section 9.

Invary 20%

Results require clinical correlation, particularly for toxin immunoassay negative or discordant results. These should be discussed with the clinical team to ensure accurate interpretation and appropriate patient patient patient. Appropriate IPC measures should be applied to patients with a positive immunoassay or NAAT.


Tables 1 and 2 address a testing algorithm that incorporates reflex testing. Vable 3 addresses a scenario where all tests are conducted simultaneously.


Table 1: Interpretation and reporting GDH immunoas	ssay followed by Toxin A and B immunoassay (followed by a 3rd tes	t if
required, see footnote*)		

	1st Assay	2nd Assay	3rd Assay (if required*)	Results	Result	Clinical comments for inclusion on laboratory reports
	GDH immunoassay	Toxin A and B immunoassay	NAAT (toxin DNA detection)		interpretive comment	
1	Negative	Not required	Notequired	Clostridioides difficile Not detected	No laboratory evidence of <i>Clostridioides</i> <i>difficile</i> infection	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.
2	Positive	Positive	Not required	Clostridioides difficile Detected	Laboratory evidence of <i>Clostridioides</i> <i>difficile</i> infection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.

Bacteriology | B 10 | Issue humber: du+ | Issue date: dd.mm.yy | Page: 17 of 37

UK Standards for Microbiology overstigations | Issued by the Standards Unit, UK Health Security Agency





Bacteriology | B 10 | Issue humber: du+ | Issue date: dd.mm.yy | Page: 19 of 37

UK Standards for Microbiolo stigations | Issued by the Standards Unit, UK Health Security Agency

,		ed Assays	3rd Assay (if	Results	Result interpretation	and B immunoassay (followed by a	
	GDH immunoassay	Toxin A and B immunoassay	required*) NAAT (toxin DNA detection)			Clinical comments for inclusion on laboratory reports	
1	Negative	Negative	Not required	Clostridioides difficile Not detected	No laboratory evidence of <i>Clostridioides</i> officile infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.	
2	Positive	Positive	Not required	Clos invioides difficile Detected	Laboratory evidence of <i>Clostridioides</i> <i>difficile</i> infection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.	
3	Positive	Negative	Negative??	Clostridioides difficile Not detected	No laboratory evidence of <i>Clostridioides</i> <i>difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> re-testing should be considered.	
4	Positive	Negative	Positive	<i>Clostridioides difficile</i> DNA Detected.	May indicate <i>Clostridioides</i> <i>difficile</i> infection requiring treatment.	Please clinically evaluate the patient and liais with microbiology for advice. Refer to local management guidelines for IPC precautions reduce risk of further transmission.	

5	Negative	Positive** (see footnotes. Report as invalid toxin result)	Negative	Clostridioides difficile Not detected	No laboratory evidence of <i>Clostridioides</i> <i>difficile</i> infection.	Consider other infectious and non-infectious causes of diarrhoea. If symptoms persist without another established cause, <i>C. difficile</i> rejesting should be considered.
6	Negative	Positive	Positive	Clostridioides difficile Detected	Laboratory evidence o <i>Clostridioides</i> <i>difficile</i> offection.	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission.
7	Positive	Negative	Invalid/inhibitory***	Invalid/inhiktory result	52n -	Please clinically evaluate the patient and, if required, liaise with microbiology for advice. Refer to local management guidelines for treatment and IPC precautions to reduce risk of further transmission. Please send a repeat sample.

Tables footnotes:

- * UK SMI recommends the use of a NAAT for all samples where the primary test is positive and the secondary test is negative. Where NAAT is not available in-house, an interim report should be result, and specimens should be referred to a laboratory capable of testing using a *C. difficile* NAAT. It should be recognised that not performing an in-house NAAT severely compromises the clinical utility of laboratory results.
- ** Where GDH and toxin A and B immunoassay witing is undertaken simultaneously, a toxin A and B immunoassay positive result in the absence of GDH and NAAT positivity should be reported as 'invalid' as there is an extremely high probability that it represents a false positive toxin A and B immunoassay positive.

*** Platforms may use different terminology, such as 'invalid' instead of 'inhibitory'.

Bacteriology | B 10 | Issue humber: du+ | Issue date: dd.mm.yy | Page: 21 of 37

UK Standards for Microbiology prestigations | Issued by the Standards Unit, UK Health Security Agency

10.2 Repeat Testing of Specimens

In the event of negative test results for CDI, where patient symptoms persist, re-testing is recommended as it is known that false negatives can occur (109)

In the event of positive test results for CDI, subsequent testing is not necessary for test of cure as *C. difficile* may persist in the bowel without causing disease (110). However, repeat testing may be required in the following cases:

- 2025 1) If a patient recovers from CDI related diarrhoea and then has a recurrence of symptoms (this could indicate recurrence of CDI – either relapse of re-infection)
- 2) If patient's symptoms persist after completing a treatment course (this rol indicate refractory CDI)
- 3) If patient develops other symptoms consistent with C. difficile intection (this could indicate severe or severe-complicated CDI or refractory CDI)

Notes:

Laboratories should adhere to a strict clinical testing criteria for epeat testing within 28 days and interpret results with caution within 1 - 2 months of the CDI diagnosis. repeat testing within This is crucial to avoid CDI misdiagnosis due to prolong shedding of *C. difficile* toxin which can vary, stopping either before or beyond 28 (111,112).

For CDI symptoms, diarrhoea should meet the specific definition provided in the document for repeat testing. For definitions of terms used in the document, refer to the scope of the document.

For repeat testing, a new faecal sample should be tested for CDI using the algorithm, regardless of whether the repeat test is thin 28 days of a positive toxin test.

Mandatory Reporting of C. difficile infection 11

In the UK there is a mandatery reporting scheme for CDI. The public health agencies within the UK, namely KHSA (England), the Public Health Agency (Northern Ireland), Public Health Scotland and Public Health Wales capture cases of CDI that meet specific criteria. Recase ensure that these cases are entered onto the relevant data capture system, where required. Details can be found in the following links:

England, Wales, and Northern Ireland:

https://bcaidcs.phe.org.uk/ContentManagement/LinksAndAnnouncements/HCAIDCS Mandatory_Surveillance_Protocol_v4.4.pdf

Welsh HCAI Surveillance Monthly Dashboard:

ttps://public.tableau.com/app/profile/victoria6405/viz/WalesHCAISurveillanceMonthly Dashboard/HBMonthlyDashboard

Scotland:

Protocol for the Scottish Surveillance Programme for Clostridioides difficile infection: user manual | National Services Scotland

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 22 of 37

<section-header><section-header><section-header><section-header><section-header><section-header><section-header><text>

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 23 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

13 Referral to reference or specialist testing **laboratories**

If isolates are sent to reference or specialist testing laboratories for processing, ensure

- Northern Ireland regional microologists: https://www.gov.uk/guidancepsestridium-difficile-ribotyping-network-cdrn-guidehttps://www.gov.uk/guidance to-services
- The UK Anaerobe Reference Unit (UKARU) in Cardiff: • https://phw.nhs.wales/services-and-teams/reference-laboratories-andspecialist-services/uk-anaerobe-reference-unit-ukaru/
- The Enteric Science Infections Service (EBIS); formerly known as the Scottish Salmonella, Snigella and Clostridioides difficile Reference Laboratory; in Glasgow, https://www.nhsggc.scot/staff-recruitment/staff-resources/laboratory-/scottish-microbiology-reference-laboratories/enteric-bacterialconsultatic hs-service/

Appendix: C. difficile culture and Identification

Culture

Alcohol shock method for culture of C. difficile

The advantage of using alcohol shock for selection of *C. difficile* is that only spores should survive this process, and it eliminates the growth of other non-sporing faecal organisms. The selective agents within the culture medium are usually based on cefoxitin and cycloserine (although others have been described), and these are usually inhibitory to most other clostridial species and other gut microbiota back The resulting growth from an active case of infection is often a pure culture difficile.

2025

It should be noted that the same medium from different suppliers may give different colonial appearances and the descriptions given here are not absolute.

- 1. Make an approximate 1:1 suspension of stool sample and 70% methanol, or 95% ethanol; in a screw capped glass bijou.
- 2. Mix by vortexing and leave to settle at room temperature for 30 min.
- 3. With a disposable pastette, inoculate two drops approx 50 -75 µl) of the deposit to cefoxitin-cycloserine egg yolk* (COFY) selective agar and streak for single colonies. At the same time, culture the control organisms on CCEY from their spore suspension and incubate as eatlined below.
- 4. Incubate anaerobically at 35°C 3 Coror 48 72hr. Cultures may be examined after overnight incubation but should not be removed from the anaerobic workstation because sporulation is inhibited on selective media and young cultures may die on exposed to air. If using anaerobic jars, cultures must not be examined before 48 hours incubation.

* Egg-yolk supplement is **6**

Identification

Colonies of C cile can be recognised by the following characteristics:

- If using egg-yolk based agar, a lack of opacity surrounding the colonies due to **N**-production of lecithinase (unlike *Paraclostridium bifermentans* [previously] Obstridium bifermentans], C. perfringens or Paraclostridium sordellii [previously -jonsulta Clostridium sordellii]). Follow individual media manufacturer's guidelines on colonial morphology.
 - Green-yellow fluorescence under long-wave UV light (see below).
 - Agglutination with C. difficile latex reagent for somatic antigen (see below).
 - MALDI TOF MS identification. This should be performed after 18-24hr subculture to FAA or blood agar. Older cultures may lead to poor identification due to spore formation.
 - NAAT. Use of a method with high analytical specificity is essential.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 25 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

For ease of identification, it is useful to sub-culture a putative C. difficile colony on Fastidious Anaerobe Agar (FAA) or blood agar (BA).

Refer to individual UK SMIs for organism identification.

Examination of plates

Colonies of *C. difficile* may be smooth or rough and may vary considerably in size. Typical colonies may be seen after sub-culture of suspect colonies from selective media on FAA or BA.

Colonial Fluorescence

- •
- Colonies of C. difficile may vary in the intensity of fluorecence, but this will appear as a green-yellow or chartreuse colour. Fluerescence is poorly developed on some agar bases and is strongest on FAA. It is important to compare fluorescence of the test colonies with that of the control organisms to clarify positive and negative results. The colonial fluorescence of cultures >48 hrs old on non-selective agars will diminise due to increased sporulation.
- Mark any suspect (fluorescent) colores on the underside of the plate with a • marker pen. Sub-culture to a FAA ABA plate and incubate anaerobically for 24-48hrs.
- **Note:** Gram staining is rare useful directly from selective agars, but from blood agar plates sub-terminal spores should be visible with most vegetative rods staining as Gran Costilive with some Gram variable forms in common with many other clostridia species. Routine Gram staining is not recommended.

Latex agglutination test for somatic antigen

Use C. difficile somatic antigen latex agglutination and follow the instructions in the kit insert.

Limitations e test

Cross-reactions with this reagent are known to occur with:

bifermentans

P. sordellii

T. glycolicus

onsult Controls

Set up controls alongside test cultures and on each new batch of medium. Control organisms required:

P. bifermentans.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 26 of 37

- P. sordellii.
- C. difficile.

Other clostridial species are commonly mistaken for C. difficile. These include 1222E C. innocuum, T. glycolicum, P. bifermentans and P. sordellii. However, these may be differentiated according to the criteria listed in Table 1.

Interpretation of results

Table A. Differential tests for recognition of colonies of C. difficile

					$\Delta \gamma$
	C. difficile	P. bifermentans	P. sordellii	T. glycolicum	C. innocuum
UV (Fluorescence) at 365nm	+	-	-		ð
Latex agglutination	+	+	+	+ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	-
Lecithinase on Brazier's CCEY medium	-	+	+	Ø	-

Organisms may be further identified if this is clinically of epidemiologically indicated.

Refer to individual UK SMIs for organism identification. ember

Culture reporting

C. difficile isolated/not isolated.

es of *C. difficile* submitted for typing Where C. difficile is confirmed - iso investigations. Further report to fol

Note: Subsequent to culture, 2 toxin test may be performed to determine whether or not the isolate is a toxin producing strain (58). Selective, differential agars are available on which toxic oroducing and non-toxin producing *C. difficile* strains can be distinguished, although care should be taken as some strains may go undetected using chromogenic media (113). As with all media, chromogenic and selective agar consultation should be ver prior to use.

References

An explanation of the reference assessment used is available in the scientific information section on the UK SMI website.

- Department of Health and Social Care. Clostridium difficile: updated guidaned UK Health Security Agency and Department of Health and Social Care Clostridioides difficile infection: how to deal with the problem 2008. 1.
- 2.
- 3.
- 4. diagnostic testing in NHS Scotland: Best practice recommendations 2024.
- Antimicrobial Resistance and Healthcare Associated Intection Scotland. 5. Protocol for surveillance of Clostridioides difficile intection- Version 5.0 2024.
- Czepiel J and others. Clostridium difficile infection: review. European Journal Clinical Microbiology & Infectious Diseases 2019: volume 38, issue 7, pages n: review. European Journal of 6. 10.1007/s10096-019-03539 1211-21.
- Chandrabos C and others. The Discosis and Treatment of Clostridium difficile 7. Diagnosed by Stool Polymerase Chain Reaction Does Not Alter the Clinical Course of Patients With Inflammatory Bowel Disease: A Case-Control Study. Official journal of the American College of Gastroenterology | ACG 2021: 10.14399/0.ajg.0000776364.63111.fe volume 116.
- Crobach MJT and others. European Society of Clinical Microbiology and 8. Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clinical Microbiology and Infection 2016: volume 22, pages \$65-\$81. 10.1016/j.cmi.2016.03.010
- Plance TD and others. Differences in outcome according to Clostridium 9. difficient testing method: a prospective multicentre diagnostic validation study of Afficile infection. The Lancet infectious diseases 2013: volume 13, issue 11, pages 936-45. https://doi.org/10.1016/S1473-3099(13)70200-7


onsultad 11.

National Institute for Health and Care Excellence (NICE). Clostridioides difficile infection: antimicrobial prescribing 2021. https://www.nice.org.uk/guidance/ng199

Mullish BH and others. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection 2024: volume 148, pages 189-219. 10.1016/j.jhin.2024.03.001

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 28 of 37

- Scottish Antimicrobial Prescribing Group (SAPG). Antimicrobial management of 12. Clostridioides difficile (C.diff) Infection (CDI) in adults (>18 years) 2022.
- 13. World Health Organisation (WHO). Diarrhoeal disease 2024.
- 14.
- Corrigan RA and others. Usefulness of the Bristol Stool Form Chart scoring system for the laboratory processing of faecal samples in suspected *Clostridioides difficile* cases. Journal of Hospital Infection 2020: volume UK Hoolth C 15.
- UK Health Security Agency (UKHSA). Annual epidemiological commentary: 16. Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2023 to 2024 2024.
- Antimicrobial Resistance and Healthcare Associated Infection Scotland. ARHAI 17. Scotland 2023 Annual Report 2024.
- Hilvers E and others. Clostridioides difficile tion following COVID-19: A 18. nationwide analysis using routine surveillance data in Wales. Journal of Hospital Infection. 10.1016/j.jhin.2024
- Public Health Agency. C.difficile and S.aureus surveillance quarterly reports 19. 2022-2024 2024.
- Kuijper EJ and others. Cos dium, Clostridioides, and Other Clostridia*. 20. Manual of Clinical Microbiology,; 2023.
- Kordus SL and other Clostridioides difficile toxins: mechanisms of action and 21. antitoxin therapettics. Nature Reviews Microbiology 2022: volume 20, issue 5, pages 285-98, 10.1038/s41579-021-00660-2
- 22. Lawson and others. Reclassification of Clostridium difficile as Clostridioides Hall and O'Toole 1935) Prévot 1938. Anaerobe 2016: volume 40, pages 95-9. https://doi.org/10.1016/i.anaerobe.2016.06.008



Schoch CL and others. NCBI Taxonomy: a comprehensive update on curation, resources and tools. Database 2020: volume 2020. 10.1093/database/baaa062

- Gröschel DHM, Toye B. Clostridium difficile Infection. Critical Reviews in 25. Clinical Laboratory Sciences 1996: volume 33, issue 3, pages 203-45. 10.3109/10408369609083061
- Brazier JS. The epidemiology and typing of Clostridium difficile. J Antimicrob 26. Chemother 1998: volume 41 Suppl C, pages 47-57. 10.1093/jac/41.suppl 3.47
- 2025 Drudy D and others. Toxin A-negative, toxin B-positive Clostridium difficile. Int 27. Infect Dis 2007: volume 11, issue 1, pages 5-10. 10.1016/j.ijid.2006.04.005
- She RC and others. Evaluation of enzyme immunoassays to detect Class 28. difficile toxin from anaerobic stool culture. Am J Clin Pathol 2009: where 131, issue 1, pages 81-4. 10.1309/ajcpmm2e7vsphnpg
- Matamouros S and others. Clostridium difficile toxin expression is inhibited by 29. the novel regulator TcdC. Molecular Microbiology 2007: volume 64, issue 5, https://doi.org/10.1111/j.1365-2958 07.05739.x pages 1274-88.
- Wolff D and others. Rapid detection of the Clostric Ministry difficile ribotype 027 30. tcdC gene frame shift mutation at position 11 analysis. Eur J Clin Microbiol Infect Dis 2009: Journe 28, issue 8, pages 959-62. 10.1007/s10096-009-0731-7
- Martínez-Meléndez A and others. An date on Clostridioides difficile Binary 31. Toxin. Toxins 2022: volume 14, is the 5, pages 305.
- Aronsson B and others. Antiperobial agents and Clostridium difficile in acute 32. enteric disease: epidemicion al data from Sweden, 1980-1982. J Infect Dis 1985: volume 151, issue Sypages 476-81. 10.1093/infdis/151.3.476
- Clabots CR and others. Acquisition of Clostridium difficile by hospitalized 33. patients: evidence for colonized new admissions as a source of infection. J Colume 166, issue 3, pages 561-7. 10.1093/infdis/166.3.561 Infect Dis 198
- 34. Samore and others. Clostridium difficile Colonization and Diarrhea at a Tertia Care Hospital. Clinical Infectious Diseases 1994: volume 18, issue 2, pages 181-7. 10.1093/clinids/18.2.181

whim JK and others. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998: volume 351, issue 9103, pages 633-6. 10.1016/s0140-6736(97)08062-8

- Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993: volume 16 Suppl 4, pages S214-8. 10.1093/clinids/16.supplement 4.s214
- el-Mohandes AE and others. Prevalence and toxigenicity of Clostridium difficile 37. isolates in fecal microflora of preterm infants in the intensive care nursery. Biol Neonate 1993: volume 63, issue 4, pages 225-9. 10.1159/000243935

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 30 of 37

36.

- Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998: 38. volume 40, issue 1, pages 1-15. 10.1016/s0195-6701(98)90019-6
- Impallomeni M and others. Increased risk of diarrhoea caused by Clostridium 39. Jan 2025 difficile in elderly patients receiving cefotaxime. BMJ 1995: volume 311, issue 7016, pages 1345-6. 10.1136/bmj.311.7016.1345
- 40. Testore GP and others. Evidence for cross-infection in an outbreak of Clostridium difficile-associated diarrhoea in a surgical unit. J Med Microbiol 1988: volume 26, issue 2, pages 125-8. 10.1099/00222615-26-2-125
- Kamthan AG and others. Clostridium difficile diarrhea induced by cance 41. chemotherapy. Arch Intern Med 1992: volume 152, issue 8, pages
- Gérard M and others. Incidence and significance of Clostridium difficile in 42. hospitalized cancer patients. Eur J Clin Microbiol Infect Dis 1988: volume 7, issue 2, pages 274-8. 10.1007/bf01963101
- Cumming AD and others. Diarrhoea due to Clostridium difficile associated with 43. antibiotic treatment in patients receiving dialysis the role of cross infection. Br Med J (Clin Res Ed) 1986: volume 292, issue (516, pages 238-9. 10.1136/bmj.292.6515.238
- Smits WK and others. Clostridium difficie infection. Nat Rev Dis Primers 2016: 44. volume 2, pages 16020. 10.1038/p.dd.2016.20
- Jazmati N and others. Evaluation for the Use of Rectal Swabs for Laboratory 45. Diagnosis of Clostridium difficient Infection. Journal of Clinical Microbiology 2018: volume 56, issue , projes 10.1128/jcm.00426-18. doi:10.1128/jcm.00426 18
- van Prehn J and others. European Society of Clinical Microbiology and 46. Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides afficile infection in adults. Clinical Microbiology and Infection 2021: volume 27, pages S1-S21. https://doi.org/10.1016/j.cmi.2021.09.038
- Johns S and others. Recurrences of Clostridium difficile diarrhea not caused 47. by the original infecting organism. J Infect Dis 1989: volume 159, issue 2, ages 340-3. 10.1093/infdis/159.2.340

Johnson S and others. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021: volume 73, issue 5, pages e1029-e44. 10.1093/cid/ciab549

National Services Scotland. National Infection Prevention and Control Manual 49. 2022.

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 31 of 37

```
UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency
```

- 50. NHS England. National infection prevention and control manual (NIPCM) for England 2022.
- Public Health Agency (PHA). Clostridioides difficile Infection 2024. 51.
- 2025 UK Health Security Agency. 30 day all-cause mortality following MRSA, MSSA 52. and Gram-negative bacteraemia and C. difficile infections: 2022 to 2023 report 2024.
- Louie TJ and others. Fidaxomicin versus Vancomycin for *Clostridium difficil* Infection. New England Journal of Medicine 2011: volume 364, issue 5, pages 422-31. doi:10.1056/NEJMoa0910812 53.
- Cornely OA and others. Fidaxomicin versus vancomycin for infection 54. Clostridium difficile in Europe, Canada, and the USA: a double-blind, noninferiority, randomised controlled trial. Lancet Infect Dis 2012: Volume 12, issue 4, pages 281-9. 10.1016/S1473-3099(11)70374-7
- Liu C and others. Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective. Antibiotics (Basel) 2023: 55. volume 12, issue 7. 10.3390/antibiotics1207
- Shetty N and others. The role of glutamate dehydrogenase for the detection of 56. Clostridium difficile in faecal samples: a greta-analysis. J Hosp Infect 2011: volume 77, issue 1, pages 1-6. 10,006/j.jhin.2010.07.024
- Goldenberg SD and others. Two glutamate dehydrogenase antigen real-57. time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect 20(0), volume 74, issue 1, pages 48-54. 10.1016/j.jhin.2009.08.01
- Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next 58. generation. Anacobe 2011: volume 17, issue 4, pages 170-4. 10.1016/j.ana de.2011.01.002
- Perrv MN 59. and others. Evaluation of the Luminex xTAG Gastrointestinal A Panel and the Savyon Diagnostics Gastrointestinal Infection Panel Patho for the detection of enteric pathogens in clinical samples. Journal of medical crobiology 2014: volume 63, issue 11, pages 1419-26. ps://doi.org/10.1099/imm.0.074773-0

- ONSUM?

Perry MD and others. Impact of the introduction of nucleic acid amplification testing on Clostridioides difficile detection and ribotype distribution in Wales. Anaerobe 2021: volume 67, pages 102313. https://doi.org/10.1016/j.anaerobe.2020.102313

Ramanan P and others. Syndromic Panel-Based Testing in Clinical 61. Microbiology. Clin Microbiol Rev 2018: volume 31, issue 1. 10.1128/cmr.00024-17

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 32 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

- Hannet I and others. Multicenter evaluation of the new QIAstat Gastrointestinal 62. Panel for the rapid syndromic testing of acute gastroenteritis. Eur J Clin Microbiol Infect Dis 2019: volume 38, issue 11, pages 2103-12. 10.1007/s10096-019-03646-4
- 63.
- Kouhsari E and others. Rapid Simultaneous Molecular Stool-Based Detection Assay. Clinical Laboratory 2019: volume 65, issue 4, pages 461-9-9. 10.7754/Clin.Lab.2018.180735 64.
- Ilges D and others. Positive impact of a diagnostic stewardship intervention on syndromic panel ordering practices and inappropriate C. difficile treatment. 65. Infection Control & Hospital Epidemiology 2024, pages 1 10.1017/ice.2024.180
- Cotter JM and others. Impact of Multiplex Testing the Identification of 66. Pediatric Clostridiodes Difficile. The Journal of Rediatrics 2020: volume 218, 10.1016/j.jpeds.2019.11.0 pages 157-65.
- al-Barrak A and others. An outbreak of on A negative, toxin B positive 67. Clostridium difficile-associated diarrasin a Canadian tertiary-care hospital. Can Commun Dis Rep 1999: volume 25, issue 7, pages 65-9. Ø
- O'Connor D and others. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated 68. diarrhea. J Clin Microbiol 2001: volume 39, issue 8, pages 2846-9. 10.1128/jcm.39.8.26462849.2001
- Musher DM and thers. Detection of *Clostridium difficile* Toxin: Comparison of 69. Enzyme Immy assay Results with Results Obtained by Cytotoxicity Assay. Journal of Amical Microbiology 2007: volume 45, issue 8, pages 2737-9. 28/jcm.00686-07 doi:10
- Turgeon DK and others. Six rapid tests for direct detection of Clostridium 70. tricile and its toxins in fecal samples compared with the fibroblast cytotoxicity ssay. J Clin Microbiol 2003: volume 41, issue 2, pages 667-70. 10.1128/jcm.41.2.667-670.2003

Yücesoy M and others. Detection of toxin production in Clostridium difficile strains by three different methods. Clin Microbiol Infect 2002: volume 8, issue 7, pages 413-8. 10.1046/j.1469-0691.2002.00440.x

Vanpoucke H and others. Evaluation of six commercial assays for the rapid 72. detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect 2001: volume 7, issue 2, pages 55-64. 10.1046/j.1469-0691.2001.00141.x

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 33 of 37

UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

- Eastwood K and others. Comparison of nine commercially available Clostridium 73. difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009: volume 47, issue 10,
- Liesenfeld O and others. Detection of Clostridium difficile toxin by enzyme immunoassay, tissue culture test and culture. Infection 1994: volume 22, issue 1, pages 29-32. 10.1007/bf01780761 Brazier JS. Role of the laboratory in investigations of Clostridium difficile diarrhea. Clin Infect Dis 1993: volume 16 Suppl 4, pages S228-33. 74.
- 75.
- Whitehead SJ and others. Is there any value in measuring faecal calprotectin in 76. Clostridium difficile positive faecal samples? Journal of medical microbiology 2014: volume 63, issue 4, pages 590-3, https://doi.org/10.1099/jmm.0.067389-0
- Stubbs SL and others. PCR targeted to the 165 22S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999: volume 37, issue 2, pages 77. 10.1128/jcm.37.2.461-463.199 461-3.
- Evre DW and others. WGS to determine the extent of Clostridioides difficile 78. transmission in a high incidence witting in North Wales in 2015. Journal of Antimicrobial Chemotherapy 348: volume 74, issue 4, pages 1092-100. 10.1093/jac/dky523
- Eyre DW and other more tandem-repeat 79. analysis and whole-genome sequencing for investigation of Clostridium difficile transmission. John Microbiol 2013: volume 51, issue 12, pages 4141-9. 10.1128/jcm 61095-13
- Llovd C ind others. Direct Clostridioides difficile ribotyping from stool using 80. capilla electrophoresis. Diagnostic Microbiology and Infectious Disease 2021: volume 99, issue 3, pages 115259. s://doi.org/10.1016/j.diagmicrobio.2020.115259
 - Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2023. pages 1-39. ++
 - British Standards Institution (BSI). BS EN12469 Biotechnology performance criteria for microbiological safety cabinets 2000. ++
- British Standards Institution (BSI). BS 5726:2005 Microbiological safety 83. cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. ++

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 34 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

82.

- Centers for Disease Control and Prevention. Guidelines for Safe Work 84. Practices in Human and Animal Medical Diagnostic Laboratories, MMWR Surveill Summ 2012: volume 61, pages 1-102.+
- 85.
- 86.
- Department of Health. Health Protection Legislation (England) Guidance. parts 1-112. 2010. ++ Gizzie N, Adukwu E. Evaluation of Liquid-Based Sweb Tra against the New Approved CL SI M40.00 87. volume 54, issue 4, pages 1152-6.2+ 10.1128/JCM.03337
- 88. Health and Safety Executive. Safe use of pneumatic air t transport systems for pathology specimens. 2009. ++
- Health and Safety Executive. Control of Substance Hazardous to Health 89. Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books. 2013. ++
- essment: A brief guide to controlling risks Health and Safety Executive. Risk as 90. in the workplace. HSE. 2014. ++
- Health and Safety Executive Avisory Committee on Dangerous Pathogens. 91. Management and operation of microbiological containment laboratories. HSE. 2019. ++
- dvibory Committee. Safe working and the prevention of 92. Health Services A aboratories and similar facilities. Books. H 2003. ++ infection in clin
- ublic Health Act (Northern Ireland) 1967 Chapter 36. 1967. ++ 93. Home Office
- Home Office. Anti-terrorism, Crime and Security Act. 2001. ++ 94.
- ticial Journal of the European Communities. Directive 98/79/EC of the Duropean Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. ++

Scottish Government. Public Health (Scotland) Act. 2008. ++

- The Welsh Assembly Government. Health Protection Legislation (Wales) 97. Guidance. 2010. ++
 - 98. UK Health Security Agency (UKHSA). Laboratory reporting to UKHSA: a guide for diagnostic laboratories. UKHSA 2023. pages 1-31. ++

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 35 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency

- The Royal College of Pathologists. The retention and storage of pathological 99. records and specimens (5th edition). pages 1-59. 2015. ++
- Tyrrell KL and others. Comparison of the Copan eSwab System with an Agar 100. Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium
- 101.
- Linon. Guidance on regulations for the transport of Lo substances 2021-2022. WHO. 2021. ++ Viprey VF and others. A point-prevalence study on community and inpettent Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November Surveill 2022: volume 27, issue 26. 10.2807/4500 7917.Es.2022.27.26.2100704 102.
- Huletsky A and others. Comparison of rectal swabs and compare for the 103. detection of Clostridioides difficile infections with a new n-house PCR assay. Microbiol Spectr 2024: volume 12, issue 6, page 22524. 10.1128/spectrum.00225-24
- Skyum F and others. Evaluation of a new (ast in-house Real-Time PCR assay 104. for detecting both Norovirus and toxiger Clostridium difficile using fecal sample and rectal swab. American the function Control 2022: volume 10.10(0).ajic.2021.08.026 50, issue 1, pages 67-71. Ø
- Kotar T and others. Evaluation of rectal swab use for the determination of enteric pathogens: a prospective study of diarrhoea in adults. Clin Microbiol 105. Infect 2019: volume 25 is the 6, pages 733-8. 10.1016/j.cmi.2018.09.026
- Freeman J, Wilcox M. The effects of storage conditions on viability of 106. Clostridium difficie vegetative cells and spores and toxin activity in human faeces. J Clip athol 2003: volume 56, issue 2, pages 126-8. 10.1136/jcp.06.2.126
- Brazie CS, Duerden BI. Guidelines for optimal surveillance of Clostridium 107. difficient infection in hospitals. Commun Dis Public Health 1998: volume 1, issue pages 229-30.

Nho SW and others. Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods for Clostridioides difficile Diagnosis. Pathogens 2021: volume 10, issue 8. 10.3390/pathogens10081049

109. Murad YM and others. False Negative Results in Clostridium difficile Testing. BMC Infectious Diseases 2016: volume 16, issue 1, pages 430. 10.1186/s12879-016-1741-6

- Fekety R and others. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989: volume 86, issue 1, pages 15-9. 10.1016/0002-9343(89)90223-4
- Zar FA and others. A comparison of vancomycin and metronidazole for the
- <text><text><text><text><text> Wenisch C and others. Comparison of vancomycin, teicoplanin, metronidazot Clin Infect Dis 1996: volume 22, issue 5, pages 813-8. 10.1093/clinids/22.5.813 Darkoh C and others. Novel one-step method for detection active-toxin-producing Clostridium difficult

Bacteriology | B 10 | Issue number: du+ | Issue date: dd.mm.yy | Page: 37 of 37 UK Standards for Microbiology Investigations | Issued by the Standards Unit, UK Health Security Agency